Assessment of the association between colchicine therapy and serious adverse events
| Autor: | Amy B. Kauffman, Brittany A. Todd, Julia E. Rawlings, Thomas Delate, Sarah J. Billups, Kara E. Canty, Theresa M. Wagner |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Colorado Gout Neutropenia Dyscrasia Gout Suppressants Cohort Studies Young Adult Internal medicine medicine Prevalence Cytochrome P-450 CYP3A Electronic Health Records Humans Pharmacology (medical) Drug Interactions Renal Insufficiency Enzyme Inhibitors Adverse effect Aged Leukopenia business.industry Case-control study Odds ratio Middle Aged medicine.disease Hematologic Diseases Surgery Case-Control Studies Insurance Health Reimbursement Cytochrome P-450 CYP3A Inhibitors Electronic data Female medicine.symptom Chemical and Drug Induced Liver Injury business Colchicine Cohort study |
| Zdroj: | Pharmacotherapy. 32(11) |
| ISSN: | 1875-9114 |
| Popis: | tudy Objective As data that prompted a 2009 labeling change detailing contraindications, precautions, and dosing recommendations for the first branded colchicine product were limited to case reports of myotoxicity and blood dyscrasias ascribed to the drug, we sought to quantify the association of colchicine therapy with serious adverse outcomes in a cohort of insured patients. Design Case-control study. Data Source Kaiser Permanente Colorado electronic data warehouses and electronic medical records. Patients Cases were patients with a creatine kinase (CK) level of at least 2000 U/L or who developed a clinically significant non–cancer-related blood dyscrasia (thrombocytopenia, neutropenia, leukopenia, aplastic anemia, or pancytopenia) between January 1, 2006, and June 30, 2009 (954 cases). Each case was matched to up to 10 controls by age, sex, and index date (date of the increased CK level or blood dyscrasia–supporting laboratory value). Controls were patients without elevated CK levels or blood dyscrasias who had a routine health maintenance examination during the same time period (index date was the date of their health maintenance examination [9007 controls]). Measurements and Main Results The primary study outcome was colchicine exposure, defined as a colchicine prescription purchase in the 100 days before the index date. The likelihood of colchicine exposure was examined with conditional logistic regression. Cases experienced a higher rate of previous colchicine exposure compared with controls (0.6% vs 0.2%, odds ratio 3.9, 95% confidence interval 1.4–10.7). In addition, cases had higher hospitalization rates (14.9% vs 5.0%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text